Inclusion Criteria:

- Histologically confirmed ovarian, peritoneal or fallopian tube cancer that has
recurred following a platinum-based regimen used at initial diagnosis

- Measurable disease

- Estimated life expectancy greater than 16 weeks

- Normal organ and marrow function

- Evidence of non-childbearing status for women of childbearing potential

- Able to swallow oral medication

Exclusion Criteria:

- Pregnant or breastfeeding

- Prior PARP inhibitor use for another cancer such as breast cancer

- Receiving any other study agents or any other anti-cancer treatment

- Known brain metastases

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to olaparib

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive hear failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- History of a different malignancy unless disease-free for at least 5 years

- Currently experiencing seizures or currently being treated with any anti-epileptic
for seizures

- Human immunodeficiency virus (HIV) positive on combination antiretroviral therapy

- Presence of gastrointestinal disorders that, in the investigator's opinion, are
likely to interfere with the absorption of olaparib, or with the patient's ability to
take regular oral medication